COVID_19のワクチン開発は第三相試験へ

英国・中国・米国のワクチン開発が第三相試験へ
米国の第三相試験の被験者は30000人超を予定。

A #Phase3 #clinicaltrial designed to evaluate if an investigational #vaccine can prevent symptomatic #coronavirus disease 2019 #COVID_19 in adults has begun.

The vaccine, known as #mRNA -1273, was co-developed by the #Cambridge , #Massachusetts -based biotechnology company #Moderna , Inc., and the #National_Institute_of_Allergy_and_Infectious_Diseases #NIAID , part of #the_National_Institutes_of_Health . #NIH

The #trial , which will be conducted at U.S. clinical research #sites , is expected to enroll 【approximately 30,000 adult volunteers】 who do not have COVID-19. #SARS_CoV_2

https://www.nih.gov/news-events/news-releases/phase-3-clinical-trial-investigational-vaccine-covid-19-begins